ClinicalTrials.gg
Not yet recruitingNCT07669155Updated Sep 30, 2026

Acute Normovolemic Hemodilution in Bone Cancer Surgery

An interventional study of Acute Normovolemic Hemodilution in Acute Normovolemic Hemodilution, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

Updated Sep 30, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for malignant bone tumors often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.

Read the detailed description

Malignant bone tumors often lead to skeletal complications, known as skeletal related events (SRE). These complications mainly include pathological fractures, severe pain, and spinal cord compression. Typically, SRE reduces overall survival rates and is associated with loss of mobility and social functioning, decreased quality of life, and significantly increased healthcare costs. Surgical resection is an important means of treating malignant bone tumors. The main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction. The surgery involves significant trauma and excessive bleeding from the wound. Therefore, there is a significant risk of perioperative blood loss and transfusion during surgery for malignant bone tumors. However, blood transfusion also brings transfusion related risks to patients, increases the incidence of postoperative complications, and increases the healthcare burden on patients and society. Therefore, it is particularly important to develop a perioperative blood management (PBM) plan for these patients. Acute normovolemic hemodilution (ANH) may help reduce allogeneic red blood cell transfusion. However, There is a lack of high-quality evidence to support the use of ANH in bone cancer surgery.

02

Conditions studied

  • Acute Normovolemic Hemodilution
03

In context

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age 18 more than years;
  2. undergoing elective bone cancer resection surgery;
  3. preoperative ≥12 g/dL;

Exclusion criteria

Exclusion Criteria:

  1. anticipated tourniquet use, endovascular balloon occlusion of the aorta or only;
  2. weight \< 50Kg or > 100Kg;
  3. (INR) >1.5 or count \<100 × 10\^9/L;
  4. cardiopulmonary insufficiency;
  5. hepatic and renal dysfunction;
  6. active infectious disease;
  7. allergy to colloid solution;
  8. pregnancy;
  9. declined participation in the study or declined blood transfusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
420 participants (estimated)

Study arms

  • No intervention
    Control group

    Except for not undergoing ANH, other care managements are the same as the experimental group

  • Experimental
    ANH group

    Patients in the ANH group had whole blood withdrawn after induction of anesthesia. Meanwhile, patients receive colloid solution according to the volume of blood withdrawn.

    Procedure: Acute Normovolemic Hemodilution

Interventions

  • ProcedureAcute Normovolemic Hemodilution

    The whole blood is withdrawn after induction of anesthesia. Blood is withdrawn from a large-bore catheter and stored in blood bags. Meanwhile, patients receive colloid solution according to the volume of blood withdrawn.

06

What researchers measure

Primary outcomes

  1. Perioperative red blood cell transfusion rate

    The number of patients receiving RBCs transfusion from the start of surgery to hospital discharge.

    Time frame: hospital discharge, an average of 10 days

Secondary outcomes

  1. The rate of perioperative transfusion of allogeneic blood products

    This includes blood products such as plasma and platelets, erythrocytes

    Time frame: hospital discharge, an average of 10 days

  2. Wound drainage volume

    Accumulated amount of wound drainage after surgery

    Time frame: hospital discharge, an average of 10 days

  3. Unplanned re-operation

    Unplanned re-operation due to bleeding, infection or other reasons

    Time frame: hospital discharge, an average of 10 days

  4. Perioperative hemoglobin concentration

    hemoglobin concentration during hospitalization

    Time frame: hospital discharge, an average of 10 days

  5. The coagulation function tests during the perioperative period

    This includes thromboelastography result

    Time frame: hospital discharge, an average of 10 days

  6. Complication

    embolic events, pulmonary complications, infection, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom

    Time frame: hospital discharge, an average of 10 days

07

Study locations

8 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Jul 2026 → Oct 2026, primary completion Jul 2026 → Oct 2028 and completion May 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 25, 2026
StartEst.
Oct 2026was Jul 2026
Primary completionEst.
Oct 2028was Jul 2026
CompletionEst.
Dec 2028was May 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added
Show 7 added (7 China)
  • Peking University First Hospital · Beijing, China
  • Beijing Jishuitan Hospital · Beijing, China
  • Fudan University Shanghai Cancer Center · Shanghai, China
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine · Shanghai, China
  • West China Hospital, Sichuan University · Sichuan, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
Sep 30, 2026
Start date
Jul 2026→Oct 2026
Sep 30, 2026
Primary completion
Jul 2026→Oct 2028
Sep 30, 2026
Study completion
May 2028→Dec 2028
Sep 30, 2026
Eligibility
2 exclusion criteria added, 2 removed
What changed in the criteria
Exclusion criteria
  • Removedusing a tourniquet;
  • RemovedBMI<18.5 Kg/m\^2;
  • Addedanticipated tourniquet use, endovascular balloon occlusion of the aorta or biopsy only;
  • Addedweight < 50Kg or > 100Kg;
Sep 30, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    7 sites added
    Show 7 added (7 China)
    • Peking University First Hospital · Beijing, China
    • Beijing Jishuitan Hospital · Beijing, China
    • Fudan University Shanghai Cancer Center · Shanghai, China
    • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine · Shanghai, China
    • West China Hospital, Sichuan University · Sichuan, China
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    Start date Jul 2026→Oct 2026
    Primary completion Jul 2026→Oct 2028
    Study completion May 2028→Dec 2028
    Eligibility 2 exclusion criteria added, 2 removed
    What changed in the criteria
    Exclusion criteria
    • Removedusing a tourniquet;
    • RemovedBMI<18.5 Kg/m\^2;
    • Addedanticipated tourniquet use, endovascular balloon occlusion of the aorta or biopsy only;
    • Addedweight < 50Kg or > 100Kg;
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07669155
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion